Markets
Borrow
Earn
Invest
Private
Security
Newsroom
More
Log In
Sign Up
Markets
Market Overview
Indices and commodities.
Digital Credit
Bitcoin treasury preferreds.
AI Stocks
The artificial intelligence theme.
Bitcoin Treasuries
Companies holding bitcoin.
Economy
Sectors, global markets and rates.
Popular Portfolios
13F filings, smart money.
Borrow
Borrow
Borrow USDT or USDC against your BTC without giving it up.
ReFi
Switch your bitcoin-backed loan and pay less interest.
Earn
Carry Trade
Borrow, invest, keep the spread.
Stock Dividends
Dividends from tokenized equities.
Invest
Private
Security
Newsroom
More
Company
About Us
Our leadership team, mission, and investors.
Whitepaper
Vision, purpose, and architecture behind Roxom.
Legal
Terms, privacy, and disclosures.
Resources
Help Center
Guides, FAQs & support.
Rulebook
Trading logic, platform rules, and fundamentals.
API Docs
Connect, authenticate, and build with our API.
Status
Current platform health and incidents.
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
1 BTC
=
- USD
BTC
SATS
Loading market data...
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HB
Harvard Bioscience Inc
HBIO
Mkt Cap
$36.7M
Volume
19.72K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Dividends
Insider
Filings
BTC
SATS
USD
1d
1w
1m
6m
YTD
1y
5y
All
Loading chart
HB
HBIO
HB
Harvard Bioscience Inc
HBIO
News
·
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity
Mkt Cap
$36.8M
Volume
19.72K
Next Earnings
November 5th
Chart
Financials
Earnings
News
About
Insider
Filings
North America Non-Viral Transfection Reagents Market Forecast to 2035 | Cell and Gene Therapy Demand Drives 8.5% CAGR and a USD 0.70 Billion Opportunity
The North America non-viral transfection reagents market is projected to grow from USD 0.34 billion in 2026 to USD 0.70 billion by 2035, representing an 8.5% CAGR. Growth is driven by rising investment in cell and gene therapy, increasing demand for nucleic acid-based treatments, and advances in scalable, low-toxicity delivery technologies. Physical methods like electroporation currently lead the market, while chemical delivery vectors are expected to show fastest growth. Clinical applications are projected to register the highest CAGR as cell and gene therapy programs advance.
GlobeNewswire Inc. · Sep 30, 2026
Harvard Bioscience Tops Q2 Revenue Views
Harvard Bioscience reported Q2 2025 GAAP revenue of $20.5 million, exceeding analyst expectations by 9.3% despite an 11.3% year-over-year decline. The company showed improved operational cash flow and continued focus on new product development in biomedical research technologies.
The Motley Fool · Aug 11, 2025
Harvard Bioscience Appoints John Duke to Board of Directors
Harvard Bioscience announced the appointment of John Duke to its board of directors and the retirement of Thomas Loewald. The company also reported its first quarter 2025 financial results.
GlobeNewswire Inc. · Jun 2, 2025
Harvard Bioscience Announces First Quarter 2025 Financial Results
Harvard Bioscience reported Q1 2025 results with revenues of $21.8 million, down from $24.5 million in Q1 2024. The company recorded a net loss of $50.3 million, which included a $48 million goodwill impairment. Adjusted EBITDA was $0.8 million, down from $1.6 million in the prior year quarter.
GlobeNewswire Inc. · May 12, 2025
Harvard Bioscience Announces CFO Transition
Harvard Bioscience announced the resignation of its Chief Financial Officer Jennifer Cote, effective upon the filing of the company's Q1 2025 report. The company has appointed Mark Frost as Interim CFO, who brings over 30 years of financial and executive experience.
GlobeNewswire Inc. · Apr 10, 2025
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025
Harvard Bioscience, a leading developer of life science technologies, announced its participation in two investor conferences in March 2025, where the company's management will host one-on-one meetings and fireside chats.
GlobeNewswire Inc. · Mar 12, 2025
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET
Harvard Bioscience, Inc. will announce its Q4 2024 financial results on March 12, 2025 and hold a conference call to discuss the results.
GlobeNewswire Inc. · Feb 24, 2025
Microelectrode Array In Vitro Market to Reach US$ 25.67 Million by 2031, Driven by Neuroscience and Animal Testing Alternatives
The global microelectrode array in vitro market is expected to grow significantly due to increasing demand for microelectrode arrays in neuroscience research and a rising focus on developing alternatives for animal testing models.
GlobeNewswire Inc. · Jan 24, 2025
Harvard Bioscience, Inc. to Participate in the Sidoti Micro Cap Conference
Harvard Bioscience, a leading developer of life science technologies, announced that its Chairman and CEO, Jim Green, and CFO, Jennifer Cote, will be presenting at the Sidoti Micro Cap Virtual Conference on January 22nd, 2025.
GlobeNewswire Inc. · Jan 13, 2025
Harvard Bioscience Schedules Third Quarter 2024 Earnings Conference Call for November 7, 2024 at 8:00 AM ET
Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its Q3 2024 financial results on November 7, 2024 and hold a conference call to discuss the results.
GlobeNewswire Inc. · Oct 29, 2024
Holdings
Open Orders (0)
Positions (0)
Order History
Dividends
Transfers
Log In
to start trading
HB
HBIO
Harvard Bioscience Inc
Buy
Sell
Market
Limit
Soon
HBIO
25%
50%
75%
Max
Pay with
—
Start Trading
Available Balance
0.00
Your Position
You don't own any HBIO yet.
Related Tickers
Earnings